### Author Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berger, A.S.</td>
<td>207</td>
</tr>
<tr>
<td>Chen, P.W.</td>
<td>137</td>
</tr>
<tr>
<td>Del Priore, L.V.</td>
<td>207</td>
</tr>
<tr>
<td>Forrester, J.V.</td>
<td>159</td>
</tr>
<tr>
<td>Hendricks, R.L.</td>
<td>120</td>
</tr>
<tr>
<td>Kaplan, H.J.</td>
<td>207</td>
</tr>
<tr>
<td>Keane-Myers, A.</td>
<td>39</td>
</tr>
<tr>
<td>Ksander, B.R.</td>
<td>137</td>
</tr>
<tr>
<td>Liu, G.</td>
<td>39</td>
</tr>
<tr>
<td>Magone, M.T.</td>
<td>90</td>
</tr>
<tr>
<td>McMenamin, P.G.</td>
<td>159</td>
</tr>
<tr>
<td>Miyazaki, D.</td>
<td>39</td>
</tr>
<tr>
<td>Niederkorn, J.Y.</td>
<td>59</td>
</tr>
<tr>
<td>Ono, S.J.</td>
<td>39</td>
</tr>
<tr>
<td>Ohashi, Y.</td>
<td>1</td>
</tr>
<tr>
<td>Ono, S.J.</td>
<td>39</td>
</tr>
<tr>
<td>Streilein, J.W.</td>
<td>11, 186</td>
</tr>
<tr>
<td>Tai, A.</td>
<td>39</td>
</tr>
<tr>
<td>Taylor, A.W.</td>
<td>72</td>
</tr>
<tr>
<td>Tezel, T.H.</td>
<td>207</td>
</tr>
<tr>
<td>Whitcup, S.M.</td>
<td>90</td>
</tr>
</tbody>
</table>
Subject Index

Adaptive immunity
  cell activation
    differentiation 15
  proliferation 14, 15
history of study 11, 12
host components 14
memory 16
tolerance 16
transfer 16

Adhesion molecules, see also
  specific molecules
  allergic conjunctivitis role 46
uveitis
    fractalkine role 97
  functions of adhesion molecules 94–96
intercellular adhesion molecule-1
  role 96
lymphocyte function-associated
  antigen-1 role 96

Age-related macular degeneration
  course 210, 211
retinal pigment epithelial transplantation
  clinical implications 213
exudative disease 211–213
rationale 210, 211
surgical outcome 211

Allergic conjunctivitis, see also
  Atopic keratoconjunctivitis, Vernal keratoconjunctivitis
animal models
  adjuvants 42
  antigens 42
compound 48/80 model 42, 43
cytokine secretion by lymphocytes 43
guinea pig 43
mouse models 43–45

  cell adhesion molecule expression 46
clinical models 45
early phase reaction 46
eosinophil cationic protein expression 50
heredity 41
late phase reaction 46–48
mast cells and mediators 51, 52
prevalence 39
seasonal disease 39
susceptibility genes 41, 42, 54
T cell response
  activation 48, 49
  chemokine expression 51
cytokines 48, 50
  subtypes 49
treatment
corticosteroids 53
cyclosporine A 53
interleukin-1 receptor antagonist 53
type I hypersensitivity 45

Anterior chamber-associated immune deviation
  antigen characteristics 62, 63
  biological significance 67, 68
  camerosplenic axis role 63, 64
  characteristics 60, 61
  corneal allograft maintenance
    197, 200, 201
Anterior chamber-associated immune deviation (continued)
cytokine modulation 66, 67
definition 2, 31
Fas ligand-induced apoptosis 64, 65
herpes simplex virus induction 132, 133
history of study 59, 60
induction 6, 7, 31–33, 65
mechanisms 65–67
model systems 65–67
T cell
cytokine profiles 61, 62
T helper subsets 67
virus induction 4
Antigen-presenting cell
costimulation 23
function 18, 19
herpes simplex keratitis 128, 129
immune privilege role 31
regulation 22, 23
specificity 19
uveitis, tissue damage 172, 173
Aqueous humor
immune response mediation 81, 82
immune suppression
calcitonin gene-related peptide 80, 81
α-melanocyte-stimulating hormone 79, 80
overview 33, 34, 75, 76
transforming growth factor-β 77–79
vasoactive intestinal peptide 80
Atopic keratoconjunctivitis, see also
Allergic conjunctivitis
clinical presentation 38, 39
course 5
cytokines 5, 6
FK-506 treatment 6
Autoimmune disease, see also Experimental autoimmune uveitis
genetic susceptibility 177, 178
herpes simplex keratitis 130–132
Mooren’s ulcer 7
T cell pathology 170
tolerance loss 102, 103, 170
uveitis 161, 163, 169–171
B cell, immune privilege 32

Blood-ocular barrier
anatomy 2, 3, 92, 93
inflammation effects 93, 94
retinal barrier 3, 92, 94
Calcitonin gene-related peptide, immune suppression in aqueous humor 80, 81
Capsule
barrier to antigen/pathogen clearance 7
degradation 7, 8
CD40, experimental autoimmune uveitis role 101
Complement
activation in uveitis 97
inhibition in immune privilege 208
Conjunctiva-associated lymphoid tissue, immunoglobulins 3
Cornea
immune privilege 29, 30, 125, 190, 191
MHC antigen expression 191–193
Corneal endothelitis, see also specific viruses
etiology 4
viruses 4
Corneal transplantation
animal models
allograft fate in normal and high-risk situations 189, 190
overview 188, 189
anterior chamber allografting studies 198
anterior chamber-associated immune deviation in maintenance 197, 200, 201
HLA matching 188, 192
immunosuppressive therapy 188
incidence 186
kidney capsule allografting studies 193, 197, 198
rejection
historical background 186, 187
prevention
anterior chamber-associated immune deviation induction 200, 201
corticosteroid 198
gene therapy 202
immunotherapy 201
interleukin-1 receptor antagonist 199, 200
Th2 response induction 200
risk factors 187, 188
sensitization mechanisms 196–198
T cell role 190, 192–196
success rate 186, 188
Corticosteroids
allergic conjunctivitis treatment 53
corneal transplantation rejection
prevention 198
Cyclosporine, allergic conjunctivitis
treatment A 53
Cytomegalovirus retinitis, overview 121
Delayed-type hypersensitivity
anterior chamber immunosuppression 75
cytokine-mediated suppression 73, 74
stages of induction 72
T helper cells 72, 73
Eosinophil cationic protein, expression in
allergic conjunctivitis 50
Epidemic keratoconjunctivitis, adenoviruses 121
Experimental autoimmune uveitis
antigens 105–107
blood-ocular barrier permeability 93, 94
CD40 role 101
clinical features 106, 107
cytokine roles
  interferon-γ 100
  interleukin-10 100
  interleukin-12 100, 101
  genetic susceptibility 107, 108, 178
  histopathology 107
  posterior uveitis pathology
    comparison 168, 169
    species 105
  T cell response 106
Experimental endotoxin-induced uveitis
anterior uveitis pathology
  comparison 167
cytokine roles
  interleukin-1 99
  interleukin-6 99, 100
  kinetics of response 102
  transforming growth factor-β 101
  tumor necrosis factor-α 99
  induction 101, 102
Fas ligand, apoptosis induction
anterior chamber-associated immune
deviation 64, 65
bystander suppression induction 176
immune privilege role
  eye 208
  tumor 138, 147, 153
  mechanism 73
ocular effects 153
Fel d1, allergic conjunctivitis induction
44, 45
FK-506, allergic conjunctivitis treatment 6
Fractalkine, uveitis role 97
Fuch’s heterochromic iridocyclitis,
etiology 4
Gut-associated lymphoid tissue, features 25
Herpes simplex keratitis
  antigen presentation 128, 129
  autoimmunity 130–132
  blindness 123
  course 124
  forms 124
  immunopathology in mouse model
    chemokines 127, 128, 132
    cytokine expression 126, 127, 132
    induction 125
    replication of virus 125, 126
    strain susceptibility 126, 130–132
    T cell response 126, 127, 130
    incidence 123, 124
    rabbit model 124
Herpes simplex virus
anterior chamber-associated immune
deviation induction 132, 133
keratitis, see Herpes simplex keratitis
latency 122, 123
retinitis 123
serotypes 122
Herpes zoster ophthalmicus
clinical manifestations 122
latency of virus 121, 122
Histamine, release in allergic
conjunctivitis 52
Human leukocyte antigen
class I gene downregulation by
tumors 145, 146
genetic susceptibility in autoimmune
disease 177, 178
matching in corneal transplantation
188, 192

Immune privilege, eye
anatomical features 1, 2, 29, 30, 151, 208
anterior chamber 28, 59
comparison with privileged nonocular
tissues 29, 151–154
components 28
cornea 29, 30, 125
factors responsible for privilege
30, 150, 151, 208, 209
history of study 27, 28, 74
immune reflex arc influence
afferent limb 31, 32
central processing 32, 33
efferent limb 33, 34
rationale 34, 35, 150
subretinal space 28, 29, 209, 210
vitreous cavity 28, 29

Immune privilege, tumors, see also
Tumor antigens
clinical significance 137, 153, 154
comparison with eye 151–154
criteria 138
escape following cancer immunization
cytotoxic T lymphocyte response 148
killer inhibitory receptor expression on
T cells 148–150
tumor antigen downregulation 148
immune suppression
interleukin-10 143, 144
transforming growth factor-β 144
vascular endothelial growth factor
144, 145
natural killer cell activity 152
prevention of tumor antigen recognition
accessory molecule
downregulation 146
Fas ligand role 138, 147, 153
HLA class I gene downregulation
145, 146

β₂-microglobulin downregulation 146
sites vs tissues 139
tumor-infiltrating lymphocyte
features 152

Immune reflex arc
afferent limb 18, 19, 22
central processing mechanism 19, 20, 23
comparison to neural reflex arc 17
efferent limb 20, 21, 23, 24
immune privilege influence
afferent limb 31, 32
central processing 32, 33
efferent limb 33, 34
overview 16–18
regulation mechanisms 21–24

Innate immunity
cell activation 13
history of study 11, 12
host components 12
pathogen-associated molecular
patterns 12, 13
regulation 13, 14

Interleukin-1
tumor secretion and immunosuppression
143, 144
natural killer cell activity 152
prevention of tumor antigen recognition
accessory molecule
downregulation 146
Fas ligand role 138, 147, 153
HLA class I gene downregulation
145, 146

Interferon-γ, experimental autoimmune
uveitis role 100

Interleukin-1
experimental endotoxin-induced uveitis
role 99
receptor antagonist
allergic conjunctivitis treatment 53
corneal transplantation rejection
prevention 199, 200

Interleukin-6, experimental
endotoxin-induced uveitis role 99, 100

Interleukin-10
tumor secretion and immunosuppression
143, 144

Interleukin-12, experimental autoimmune
uveitis role 100, 101

Intraocular inflammation, see Uveitis

Killer inhibitory receptor, expression on
T cells 148–150
T cell (continued)
immunopotentiation 32
killer inhibitory receptor expression in tumor escape 148–150
uveitis response 170–172, 174, 176–178
 Tear fluid, viruses 4, 5
Tolerance
antigen-presenting cell mechanisms 23
autoimmune disease development 102, 103, 170
definition 16
Toxoplasmosis, see Murine ocular toxoplasmosis
Transforming growth factor-β
experimental endotoxin-induced uveitis role 101
immune suppression in aqueous humor 77–79
tumor secretion and immunosuppression 144
Transplantation, see Corneal transplantation, Retinal transplantation
Tumor antigens, see also Immune privilege, tumors
differentiation antigens 140
identification 139, 140
immunogenicity 137
intron transcription abnormalities 142
melanoma antigen gene 141, 142
mutant antigens 141
overexpression of normal antigens 141
tumor escape following cancer immunization
cytotoxic T lymphocyte response 148
killer inhibitory receptor expression on T cells 148–150
tumor antigen downregulation 148
Tumor necrosis factor-α, experimental endotoxin-induced uveitis role 99
Uveitis, see also Experimental autoimmune uveitis, Experimental endotoxin-induced uveitis, Murine ocular toxoplasmosis anterior uveitis
features 163
pathology infectious disease 163
noninfectious disease 165
autoimmunity 161, 163, 169–171
blood-ocular barrier permeability 93, 94
causes 90, 160, 161, 163
cell adhesion molecules fractalkine role 97
functions 94–96
intercellular adhesion molecule-1 role 96
lymphocyte function-associated antigen-1 role 96
chemokine roles 97, 98
classification 90
clino-pathological features 159, 160, 175
complement activation 97
damage mechanisms antigen-presenting cells 172, 173
bystander damage 173
clinical spectrum 175
cytokines 174, 175
effector cells 174
definition 159
genetic susceptibility 177, 178
immune response regulation and dysfunction 175–178
infectious disease 160, 161
intraocular inflammation nomenclature 159
lens-induced uveitis 103, 105
melanin protein-induced uveitis 103, 167
posterior uveitis features 165
pathology infectious disease 165, 166
noninfectious disease 166
T cell response 170–172, 174, 176–178
Vascular endothelial growth factor 144, 145
Vasoactive intestinal peptide, immune suppression in aqueous humor 80
Vernal keratoconjunctivitis, see also Allergic conjunctivitis
clinical presentation 38, 39
course 5
nerve growth factor expression 50, 51